Orexigen (NASDAQ:OREX) is looking at a PDUFA date of June 11 to find out from the FDA if it can bring its weight-control combo, NB32/Contrave (sustained-release bupropion/naltrexone), to market this summer. The major regulatory hurdle of FDA clearance for the US market is well known to provide a strong price movement whether up or down and in OREX's case it looks to be about 40-50% move either way. Does it work well enough to get that FDA nod? Is it safe enough for the FDA? Will it make appreciable sales once it does? Yes, yes, and yes.
FDA Reception Positive...
In December of 2010, an FDA advisory-committee panel reviewed Contrave's four Phase III studies and voted 13-7 that...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|